Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6517
    -0.0019 (-0.29%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    108,562.02
    +1,808.18 (+1.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6033
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0902
    +0.0022 (+0.20%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Johnson & Johnson earnings top expectations

Getty Images. Goldman Sachs lowers its rating for Johnson & Johnson to sell from neutral.

Johnson & Johnson (NYSE: JNJ) delivered quarterly earnings that topped analysts' expectations on Tuesday, but revenue was light.

Shares of J&J edged lower in premarket trading following the announcement. (Get the latest quote here.) (NYSE: JNJ)

The diversified health care giant posted third-quarter adjusted earnings of $1.49 per share, down from $1.50 a share in the year-earlier period.

Revenue fell to $17.1 billion from $18.47 billion a year ago.

Analysts expected the company to post earnings per share of $1.45 on revenue of $17.45 billion, according to a Thomson Reuters consensus estimate.

J&J also forecast full-year adjusted earnings of $6.15 a share to $6.20 a share.

ADVERTISEMENT

Earlier Tuesday, the drugmaker said it would buy back up to $10 billion of common stock.

The company said on Tuesday it had about 2.77 billion shares of common stock outstanding as of Sept. 27.

On Friday , J&J said it has begun clinical trials for an Ebola vaccine in Sierra Leone as part of a new study being conducted in the nation's Kambia district, the site of some of the most recent cases.

J&J's stock has lagged in the last year when compared to its rival Pfizer (NYSE: PFE), having fallen more than 5 percent in that time, while Pfizer shares have risen more than 13 percent, according to FactSet data.

Reuters contributed to this report.



More From CNBC

  • Top News and Analysis

  • Latest News Video

  • Personal Finance